pH Associates Ltd (an OPEN Health company) and Cisiv Ltd combined best in class consulting services, RWE expertise and fit-for-purpose technology, which delivered value both to AbbVie and to NHS Trusts. This article highlights how this partnership achieved the best results.
The Treat-to-Target recommendations for the management of rheumatoid arthritisaim to achieve
high remission rates and improved function. A national UK audit was conducted
to assess how well NHS Trusts were following international recommendations.
In 2010, an international task force developed therapeutic
recommendations on treating rheumatoid arthritis (RA) to target. The aim of
these ‘Treat to Target’ (T2T) recommendations was to improve RA management and
clinical outcomes for patients. The challenge was then to assess how well these
recommendations were embedded in standard clinical practice in the UK, and
whether the recommendations (or the practice of auditing) drove improvements in
A steering committee of rheumatologists worked with AbbVie to develop a national
audit of secondary care NHS rheumatology units. The audit was aimed at
establishing the compliance with the T2T recommendations and included data from
38 NHS facilities in elation to 1,571 newly diagnosed RA patients.
pH Associates (an
OPEN Health company) consulted with NHS clinicians to develop an audit tool
which would meet their needs, deliver data periodically and ultimately answer
their clinical questions. Over a 6 month period, assistance was provided to
gain appropriate NHS permissions and the audit was then rolled out nationally.
pH Associates and Cisiv worked closely to design
the optimal electronic platform to collect data directly from clinicians. For a
minimum of 12 months, data on disease history, management and outcomes were
collected at each visit the patient attended the NHS facility.
Cisiv ensured that the data collection tool was intuitive,
streamlined and easy to use. In addition, the platform enabled NHS sites to
have real-time access to their own data.